Verrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315,…
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022 Non-melanoma skin cancers are the most common form of cancer in the U.S., with over 5 million diagnoses each…